Overview
Androlabs is a global pharmaceutical company focused on men’s health. It develops and sells testosterone replacement and erectile dysfunction medications, aiming to reduce the life expectancy gap between men and women. Beyond products, Androlabs builds an inclusive community for men, addressing knowledge gaps and overlooked health issues, and encourages openness about vulnerability. The company operates in over 20 countries in Europe and Australia and works with healthcare professionals to improve men’s health outcomes. It belongs to the same corporate group as Simple Pharma and seeks new partners who share a passion for men’s health. Its goal is to extend healthy, active lives for men by providing targeted therapies and support, while challenging stereotypes and facilitating better care for men across multiple markets.
Work here?Claim your company
Simplify's take
What believers are saying
- July 27, 2026 France launch with Majorelle extends Testavan across major European markets.
- August 25, 2026 UK marketing authorization adds another Testavan presentation and market access.
- August 13, 2026 Switzerland partnership with EffRx broadens commercial reach and validation.
What critics are saying
- Testavan dependence concentrates revenue risk in one testosterone franchise.
- France was the last major European market; rollout saturation limits near-term growth.
- Men’s health remains underdiagnosed, so payer friction and physician adoption can slow sales.
What makes Androlabs unique
- Androlabs is the only global pharmaceutical company dedicated exclusively to men’s health.
- Its portfolio centers on Testavan and Vitaros, not broad-spectrum pharmaceuticals.
- A dedicated corporate structure launched October 27, 2026 for faster product expansion.
Help us improve and share your feedback! Did you find this helpful?